Company Overview

Concord Medical Services Holdings Limited (NYSE: CCM) is a China-based healthcare services provider specializing in cancer diagnosis and radiation therapy. The company operates in the oncology healthcare services industry, with a core focus on providing advanced radiotherapy and diagnostic imaging services to hospitals and medical institutions. Its primary revenue drivers have historically included management services, equipment leasing, and technical support related to radiotherapy and imaging centers.

Founded in 1997, Concord Medical was among the earliest private operators to introduce advanced radiation therapy equipment into Chinese hospitals. The company expanded rapidly through partnerships with public hospitals, leveraging its ability to finance, install, and operate high-end medical equipment. Over time, Concord Medical evolved from an equipment-centric service provider into a broader oncology-focused healthcare company, while also navigating regulatory changes and shifts in China’s healthcare reimbursement environment.

Business Operations

Concord Medical conducts its business primarily through the operation and management of radiotherapy and diagnostic imaging centers located within partner hospitals. Its core operating segments have included Radiotherapy and Diagnostic Imaging Services, which generate revenue through long-term cooperation agreements involving equipment leasing, technical services, and revenue-sharing arrangements with hospitals.

The company’s operations are predominantly domestic within China, and it controls key assets such as linear accelerators, PET-CT scanners, and other advanced imaging and radiation therapy equipment. Concord Medical has operated through numerous project companies and subsidiaries established to manage individual hospital partnerships. Over time, some centers were consolidated, restructured, or divested as the company adjusted its portfolio in response to regulatory, financial, and operational considerations.

Strategic Position & Investments

Strategically, Concord Medical has positioned itself as a specialized oncology services provider with an emphasis on capital-intensive, high-technology treatment modalities. Its growth initiatives historically focused on expanding the number of hospital-based radiotherapy centers and upgrading technology to include more precise and advanced treatment solutions.

The company has made selective investments in hospital assets and oncology-related service platforms, including involvement in specialized cancer hospitals and outpatient oncology facilities. Concord Medical has also explored opportunities in integrated cancer care models, combining diagnostics, treatment, and follow-up services. However, public disclosures indicate that the pace and scale of expansion have fluctuated, reflecting both internal financial priorities and external policy developments in China’s healthcare sector.

Geographic Footprint

Concord Medical’s operations are concentrated primarily in Mainland China, where it has partnered with hospitals across multiple provinces and major metropolitan areas. The company is headquartered in Beijing, which serves as its central management and administrative hub.

While Concord Medical is listed in the United States, its operational footprint outside China has been limited. International influence has been largely financial and capital-market–oriented rather than operational, with no significant long-term overseas clinical operations disclosed in public filings.

Leadership & Governance

Concord Medical was founded by Jianzhong Liu, who has played a central role in shaping the company’s strategy and expansion model. The leadership team has generally combined medical industry expertise with financial and operational management experience, reflecting the company’s hybrid model of healthcare delivery and asset management.

Key executives disclosed in recent public filings include:

• Jianzhong Liu – Chairman of the Board
• Jianyu Yang – Chief Executive Officer
• Xianguo Wang – Chief Financial Officer
• Jian Wang – Director

The company’s governance structure follows U.S. public company standards due to its NYSE listing, with a board of directors overseeing strategy, risk management, and compliance. Management has emphasized disciplined capital allocation and operational efficiency amid ongoing changes in China’s healthcare regulatory and reimbursement landscape.